{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-000959","form_type":"8-K","ticker":"AEMD","cik":"0000882291","company_name":"AETHLON MEDICAL INC","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.903183+00:00","generated_at":"2026-05-16T03:10:39.978208+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aethlon Medical Q3 FY2026: cash $7.0M; operating loss $2.06M up 13.6% YoY","bullets":["Cash balance of ~$7.0M as of Dec 31, 2025; no revenue reported.","Q3 operating loss of $2.06M vs $1.81M in prior year, driven by higher payroll costs.","Nine-month operating expenses down 26.9% to $5.36M from $7.34M YoY.","Cohort 2 of Australian oncology trial progressing; Hemopurifier compatibility study with SLAMB system underway.","Preclinical Long COVID data published on bioRxiv; submitted for peer review."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-000959","json":"https://secwatch.observer/filing/0001683168-26-000959.json","markdown":"https://secwatch.observer/filing/0001683168-26-000959.md","text":"https://secwatch.observer/filing/0001683168-26-000959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882291/000168316826000959/0001683168-26-000959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882291/000168316826000959/aethlon_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:10:39.978208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}